ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

White House Order Poses Difficulties For NIH Peer Review

April 2, 1993

NCAB Committee, SORDS Agree On New Training Grants In Surgical Oncology

January 11, 1985

Afatinib Delays Tumor Growth In LUX-Head and Neck 1 Study

October 31, 2014

Cost Of Cancer:$40 Billion In 1980, Now Probably Between $50-80 Billion; “The Tip Of The Iceberg”

February 25, 1983

Centers May Become More specialized, Klausner Tells AACI

April 26, 1996

NCI To Proceed With Guidelines Unless Board Strongly Disagree

May 9, 1980